Apolipoprotein B-100-targeted negatively charged nanoliposomes for the treatment of dyslipidemia

Amirhossein Sahebkar, A. Badiee, M. Hatamipour, M. Ghayour-Mobarhan, M.R.E. Jaafari

    Research output: Contribution to journalArticle

    7 Citations (Scopus)

    Abstract

    © 2015 Elsevier B.V. Background: Anionic nanoliposomes can interact with serum lipoproteins and regulate lipid metabolism through several mechanisms. This study aimed to evaluate the lipid-modifying effects of anionic immunoliposomes targeted against apoB, an important component of atherogenic lipoproteins. Methods: Two sets of nanoliposomes (20. mM) were prepared with low (including soy phosphatidylcholine [SPC] and egg phosphatidylglycerol [EPG]) and high (including hydrogenated soy phosphatidylcholine [HSPC] and distearoyl phosphatidylglycerol [DSPG]) phase transition temperature values without cholesterol. In each set, the anionic phospholipid (EPG or DSPG) constituted 75% of total phospholipid content. Immunoliposomes were prepared by conjugating a monoclonal antibody against apoB-100 to the liposomal surface using a post-insertion technique. Fluorescently-labeled immunoliposomes were assessed for their uptake by J774.A1 macrophages. Lipid-modifying effects of immunoliposomes were tested at different doses (50, 100 or 200. μmole/g weight) using a tyloxapol-induced hyperlipidemic mouse model. Blood sampling was performed 1. h after the injection of each immunoliposomal formulation. Results: ApoB-targeted HSPC/DSPG and SPC/EPG nanoliposomes were both taken up by cultured macrophages but the uptake rate was higher with the former formulation. Both immunoliposomal formulations significantly reduced serum LDL-cholesterol concentrations of hyperlipidemic animals at all tested doses (p
    Original languageEnglish
    Pages (from-to)71-78
    JournalColloids and Surfaces B: Biointerfaces
    Volume129
    DOIs
    Publication statusPublished - 2015

    Fingerprint Dive into the research topics of 'Apolipoprotein B-100-targeted negatively charged nanoliposomes for the treatment of dyslipidemia'. Together they form a unique fingerprint.

    Cite this